HEPA Stock — Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals Inc (HEPA)

Updated October 16, 2026.

HEPA is a Stock. Its deepest 1-year drawdown was 60.7%.

Hepion Pharmaceuticals is a biopharmaceutical company developing treatments for hepatocellular carcinoma, metabolic liver diseases, and chronic liver diseases, with a lead drug candidate called Rencofilstat that targets cyclophilin enzymes to reduce liver fibrosis, inflammation, and tumor burden. The company does not currently distribute dividends or other income to shareholders. This security appeals to investors seeking exposure to early-stage drug development with high risk and potential for significant capital appreciation rather than current income.

HEPA performance

Returns are updating. HEPA's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 60.7%.

HEPA key facts

Asset type

Stock

Asset class

Equity

Inception date

02/10/2014

Distribution frequency

None

Last close

$0.09 (as of 2026-10-16)

Market cap

$8,987,174

Average volume

163.0

Payment date

06/03/2019

Beta

1.751

Payout ratio

0.0%

EPS

$-0.19

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HEPA risks and drawbacks

The deepest 1-year drawdown on record here is 60.7%.

Who may consider HEPA — and who may not

It is a weaker fit for investors who need monthly cash flow (HEPA does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on HEPA

• All tickers starting with H

Tagged: Healthcare.

Frequently asked questions